SIETES :: 93213 citas

Resultados de la búsqueda por FACET REFINAR BÚSQUEDA

1.

Bonet Monné S. Dades d'eficàcia dels IECA, ARA II i la combinació d'ambdós grups de fàrmacs. Butlletí d'Informació Terapèutica 2010;22:7-12. [Ref.ID 88270]

2.

O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 2006;368:794-803. [Ref.ID 77960]

3.

Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138:593-602. [Ref.ID 65601]

4.

Snow V, Weis KB, Mottur-Pilson C, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence based for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003;138:587-92. [Ref.ID 65600]

5.

Tattersfield AE. On-demand relief treatment for asthma. Authors' reply. Lancet 2001;357:1882-3. [Ref.ID 57247]

6.

Joseph J, Badrinath P. On-demand relief treatment for asthma. Lancet 2001;357:1882. [Ref.ID 57246]

7.

Lipworth BJ, Currie G, Fowler S. On-demand relief treatment for asthma. Lancet 2001;357:1882. [Ref.ID 57245]

8.

Redón i Mas J. Reflexiones sobre el estudio INSIGHT. Rev Clin Esp 2000;200:21-7. [Ref.ID 56270]

9.

Gil Extremera B. Reducción de la morbimortalidad por el tratamiento con calcioantagonistas. Rev Clin Esp 2000;200:13-20. [Ref.ID 56269]

10.

Roca-Cusachs Coll A. Calcioantagonistas y riesgo cardiovascular. Rev Clin Esp 2000;200:4-12. [Ref.ID 56268]

11.

Lipworth BJ. Inhaled budesonide/formoterol combination: viewpoint. Drugs 2001;61:79-80. [Ref.ID 54890]

12.

Boulet LP. Inhaled budesonide/formoterol combination: viewpoint. Drugs 2001;61:79. [Ref.ID 54889]

13.

McGavin J K, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs 2001;61:71-8. [Ref.ID 54888]

14.

Ykï-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000;60:975-83. [Ref.ID 54148]

15.

Anónimo. Furberg replies to critics. Scrip 2000;2575:23. [Ref.ID 52785]

16.

Anónimo. Experts condemn Furberg's meta-analysis. Scrip 2000;2574:22. [Ref.ID 52775]

17.

Anónimo. Furberg attacks calcium antagonists again. Scrip 2000;2570/71:26. [Ref.ID 52547]

18.

Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000;283:3177-9. [Ref.ID 51620]

19.

Psaty B M, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal F R, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90. [Ref.ID 46651]

20.

Maggioni AP. Calcio-antagonisti: tra consumi ed evidenze. Informazioni sui Farmaci 1998;22:70-2. [Ref.ID 39835]